Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2014; 20(1): 310-318
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.310
Published online Jan 7, 2014. doi: 10.3748/wjg.v20.i1.310
Table 3 Survival in the three trials included in the meta-analysis
| Ref. | No. of patients | Median survival (mo) | 1-yr survival (%) | HR (95%CI) | P value |
| Koizumi et al[16] | 148 (Group A) | 11.0 | 46.7 | 0.77 (0.61-0.98) | < 0.0001 |
| 150 (Group B) | 13.0 | 54.1 | |||
| Narahara et al[18] | 47 (Group A) | 10.5 | 44.9 | 0.86 (0.66-1.11) | 0.233 |
| 48 (Group B) | 12.8 | 52.0 | |||
| Wang et al[19] | 160 (Group A) | 11.0 | 46.3 | 0.55 (0.34-0.90) | 0.020 |
| 155 (Group B) | 14.0 | 61.0 | |||
| Total | 355 (Group A) | 10.9 | 46.3 | 0.77 (0.66-0.91) | 0.000 |
| 353 (Group B) | 13.4 | 56.8 |
-
Citation: Liu GF, Tang D, Li P, Wang S, Xu YX, Long AH, Zhou NL, Zhang LL, Chen J, Xiang XX. S-1-based combination therapy
vs S-1 monotherapy in advanced gastric cancer: A meta-analysis. World J Gastroenterol 2014; 20(1): 310-318 - URL: https://www.wjgnet.com/1007-9327/full/v20/i1/310.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i1.310